Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM2902 in Advanced Solid Tumors
NCT05805956Phase 2Unknown
- Sponsor
- ImmuneOnco
- Start
- Feb 2022
- Primary completion
- Oct 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IMM2902 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), gastric cancer (GC), biliary tract cancer (BTC), sponsored by ImmuneOnco. Status: unknown.
02
Drugs
IMM2902
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)gastric cancer (GC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05805956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05805956.